Abstract
The resurgence of tuberculosis and the surge of multidrug-resistant clinical isolates of Mycobacterium tuberculosis have reaffirmed tuberculosis as a primary public health concern. In this review we describe some new findings on the pharmacological status of fluoroquinolones derivatives (Gatifloxacin, Moxifloxacin and Sitafloxacin), new macrolides (Clarithromycin, Azithromycin and Roxithromycin), new rifamycin derivatives (Rifapentin, Rifabutin and Rifalazil) and new oxazolidinones (Linezolid and PNU 100480). We describe also other type of agents that are being developed as antimycobacterial drugs. Some of these are under clinical investigation, while others are considered to be promising candidates for future development. Among them, nitroimidazopyrans, new ketolides, Isoxyl (ISO), pyrroles derived from BM 212, Mefloquine and Diarylquinoline R207910 are discussed. We also describe the mechanism of drug resistance in mycobacteria, as well as new potential targets.
Keywords: Mycobacterium tuberculosis, Mycobacterium avium complex, tuberculosis, drug-resistance, new targets, promising drugs, anti-TB therap, drug-combinations
Infectious Disorders - Drug Targets
Title: New Trends in Development of Antimycobacterial Compounds
Volume: 6 Issue: 2
Author(s): M. Biava, G C. Porretta, D. Deidda and R. Pompei
Affiliation:
Keywords: Mycobacterium tuberculosis, Mycobacterium avium complex, tuberculosis, drug-resistance, new targets, promising drugs, anti-TB therap, drug-combinations
Abstract: The resurgence of tuberculosis and the surge of multidrug-resistant clinical isolates of Mycobacterium tuberculosis have reaffirmed tuberculosis as a primary public health concern. In this review we describe some new findings on the pharmacological status of fluoroquinolones derivatives (Gatifloxacin, Moxifloxacin and Sitafloxacin), new macrolides (Clarithromycin, Azithromycin and Roxithromycin), new rifamycin derivatives (Rifapentin, Rifabutin and Rifalazil) and new oxazolidinones (Linezolid and PNU 100480). We describe also other type of agents that are being developed as antimycobacterial drugs. Some of these are under clinical investigation, while others are considered to be promising candidates for future development. Among them, nitroimidazopyrans, new ketolides, Isoxyl (ISO), pyrroles derived from BM 212, Mefloquine and Diarylquinoline R207910 are discussed. We also describe the mechanism of drug resistance in mycobacteria, as well as new potential targets.
Export Options
About this article
Cite this article as:
Biava M., Porretta C. G, Deidda D. and Pompei R., New Trends in Development of Antimycobacterial Compounds, Infectious Disorders - Drug Targets 2006; 6 (2) . https://dx.doi.org/10.2174/187152606784112173
DOI https://dx.doi.org/10.2174/187152606784112173 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Roles of Antimicrobial Peptides in Innate Host Defense
Current Pharmaceutical Design Identification and Investigation of Chalcone Derivatives as Calcium Channel Blockers: Pharmacophore Modeling, Docking Studies, In vitro Screening, and 3D-QSAR Analysis
Current Computer-Aided Drug Design New Antifolate Inhibitors for Mycobacterium avium
Medicinal Chemistry Entropy Model for Multiplex Drug-Target Interaction Endpoints of Drug Immunotoxicity
Current Topics in Medicinal Chemistry Heat Shock Protein-60 and Risk for Cardiovascular Disease
Current Pharmaceutical Design The Type III Secretion System as a Source of Novel Antibacterial Drug Targets
Current Drug Targets Design, Synthesis and Biological Evaluation of Anti-tuberculosis Agents based on Bedaquiline Structure
Medicinal Chemistry Galvez-Markov Network Transferability Indices: Review of Classic Theory and New Model for Perturbations in Metabolic Reactions
Current Drug Metabolism Recent Patents in Autophagy and Immune Response
Recent Patents on Inflammation & Allergy Drug Discovery Targeting Bacterial Metalloenzymes: A New Strategy for the Development of Anti-Infective Agents
Anti-Infective Agents in Medicinal Chemistry Pleuroparenchymal Fibroelastosis: Its Pathological Characteristics
Current Respiratory Medicine Reviews Antimalarial Drugs and their Useful Therapeutic Lives: Rational Drug Design Lessons from Pleiotropic Action of Quinolines and Artemisinins
Current Drug Discovery Technologies Chemical Composition, Antioxidant and Antimicrobial Activities of the Essential Oils of Three Algerian Lamiaceae Species
Current Nutrition & Food Science Synthesis and In Vitro Antibacterial Screening of some New 2,4,6-Trisubstituted-1,3,5-Triazine Derivatives
Letters in Drug Design & Discovery The Central Role Played by Peptides in the Immune Response and the Design of Peptide-Based Vaccines Against Infectious Diseases and Cancer
Current Drug Targets Occupational Respiratory Pathology in Russia: Current Trends and Challenges
Current Respiratory Medicine Reviews Meet Our Executive Guest Editor
Current Topics in Medicinal Chemistry Crystallization of Cytochromes P450 and Substrate-Enzyme Interactions
Current Topics in Medicinal Chemistry Emerging Roles for the CD36 Scavenger Receptor as a Potential Therapeutic Target for Corneal Neovascularization
Endocrine, Metabolic & Immune Disorders - Drug Targets Gene Mining and Functional Genomics in Human Osteoarthritis
Current Genomics